Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).
Adrienne G WaksEmily L ChenNoah GrahamAnna Mae FreyKenneth AlmeidaVictoria AttayaVictoria AttayaIbrahim M AbbassAnita FungJesse SussellPatricia CortazarCaroline HarveyDenise LethMeredith FaggenNatalie SinclairJeanna WalshNadine M TungSarah SinclairSteve LoDenise YardleyVicente ValeroJane MeiselTarah Jean BallingerSylvia AdamsLisa Anne CareyJulia K RauchVandana G AbramsonNicole O WilliamsWendy Y ChenJosé Pablo LeoneSusan T SchumerNabihah TayobSara M TolaneyPublished in: JCO oncology practice (2024)
SC administration of HP shortened patient time burden by approximately 1 hour. SC drug administration can facilitate faster workflows for health care professionals and improve patients' breast cancer treatment experience.
Keyphrases
- epidermal growth factor receptor
- metastatic breast cancer
- healthcare
- end stage renal disease
- drug administration
- ejection fraction
- newly diagnosed
- early stage
- blood pressure
- clinical trial
- study protocol
- prognostic factors
- randomized controlled trial
- peritoneal dialysis
- high dose
- case report
- low dose
- phase iii
- patient reported outcomes
- young adults
- high resolution
- mass spectrometry
- social media
- childhood cancer
- health information